Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Vincenzo Pio Di Noia, Ettore D'Argento, Sara Pilotto, Emanuele Vita, Miriam Grazia Ferrara, Paola Damiano, Marta Ribelli, Maria Antonella Cannella, Antonella Virtuoso, Andrea Fattorossi, Giovanni Luca Ceresoli, Michele Milella, Giordano Domenico Beretta, Giampaolo Tortora, Emilio Bria
Entra nei temi di ricerca di 'Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study'. Insieme formano una fingerprint unica.